Case report: Successful outcome of treatment using rituximab in an adult patient with refractory minimal change disease and β-thalassemia complicating autoimmune hemolytic anemia
Zhuang J, Zhao Z, Zhang C, Song X, Lu C, Tian X, Jiang H. Case report: Successful outcome of treatment using rituximab in an adult patient with refractory minimal change disease and β-thalassemia complicating autoimmune hemolytic anemia. Frontiers In Medicine 2022, 9: 1059740. PMID: 36405580, PMCID: PMC9669371, DOI: 10.3389/fmed.2022.1059740.Peer-Reviewed Case Reports and Technical NotesMinimal change diseaseAutoimmune hemolytic anemiaIdiopathic nephrotic syndromeRefractory nephrotic syndromeAdult patientsΒ-thalassemia minorNephrotic syndromeChange diseaseHemolytic anemiaPan B cell marker CD20Treatment of MCDHigh-dose glucocorticoid therapyAdverse effectsClinical complete remissionAdministration of rituximabChimeric monoclonal antibodyLess adverse effectsΒ-thalassemiaAgent regimensComplete remissionGlucocorticoid therapyFrequent relapsesGlucocorticoid dependenceGlucocorticoid resistanceCommon cause